An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab
暂无分享,去创建一个
G. Beretta | A. Santoro | M. Roncalli | L. Rimassa | L. Giordano | C. Carnaghi | A. Destro | F. Sclafani | F. Lutman | P. Colombo | A. Zanello | Sergio G. Stinco
[1] D. Cunningham,et al. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study. , 2014, Clinical colorectal cancer.
[2] L. Ellis,et al. Predictive Biomarkers for Bevacizumab: Are We There Yet? , 2013, Clinical Cancer Research.
[3] R. Simes,et al. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab* , 2013, Cancer medicine.
[4] E. Lerma,et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas , 2012, British Journal of Cancer.
[5] E. Maccaroni,et al. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients , 2012, British Journal of Cancer.
[6] P. Muti,et al. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials , 2010, Journal of experimental & clinical cancer research : CR.
[7] G. Jayson,et al. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors , 2009, British Journal of Cancer.
[8] J. Reid,et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Park,et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer , 2009, BMC Cancer.
[10] N. Funel,et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Minn,et al. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer , 2009, British Journal of Cancer.
[12] D. Durden,et al. PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis. , 2009, Current pharmaceutical design.
[13] Pei-Fang Su,et al. The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer , 2008, Diseases of the colon and rectum.
[14] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Chung,et al. Hypoxia Inducible Factor-1–Independent Pathways in Tumor Angiogenesis , 2007, Clinical Cancer Research.
[16] Abdul Waheed,et al. Carbonic Anhydrase IX Is Highly Expressed in Hereditary Nonpolyposis Colorectal Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.
[17] M. van Engeland,et al. Stromal Expression of Hypoxia Regulated Proteins Is an Adverse Prognostic Factor in Colorectal Carcinomas , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[18] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] T. Aittokallio,et al. Biochemical and clinical approaches in evaluating the prognosis of colon cancer. , 2006, Anticancer research.
[20] D. Chung,et al. Hypoxic Regulation of Vascular Endothelial Growth Factor through the Induction of Phosphatidylinositol 3-Kinase/Rho/ROCK and c-Myc* , 2006, Journal of Biological Chemistry.
[21] A. Jubb,et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Jubb,et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. , 2005, Journal of the National Cancer Institute.
[23] F. Kabbinavar,et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[26] D. Chung,et al. Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer , 2004, Cancer Research.
[27] A. Harris,et al. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer , 2003, British Journal of Cancer.
[28] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[29] Roderick Turner,et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] Abdul Waheed,et al. Differential Expression of Cytoplasmic Carbonic Anhydrases, CA I and II, and Membrane-Associated Isozymes, CA IX and XII, in Normal Mucosa of Large Intestine and in Colorectal Tumors , 2001, Digestive Diseases and Sciences.
[31] J. Pastorek,et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.
[32] W. Sly,et al. Immunohistochemistry of Carbonic Anhydrase Isozyme IX (MN/CA IX) in Human Gut Reveals Polarized Expression in the Epithelial Cells with the Highest Proliferative Capacity , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[33] Leonard,et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.
[34] R. Kramer,et al. Expression of the C‐Met/HGF receptor in human breast carcinoma: Correlation with tumor progression , 1997, International journal of cancer.
[35] B. Nordlinger,et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[37] J. Folkman. What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.
[38] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[39] A. Gasbarrini,et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. , 2013, The Lancet. Oncology.
[40] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[41] H. Hurwitz,et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. , 2009, The oncologist.
[42] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[43] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] B. Elliott,et al. Constitutive activation of met kinase in non‐small‐cell lung carcinomas correlates with anchorage‐independent cell survival , 2002, Journal of cellular biochemistry.